Arthur Holden, Shaf Yousaf, Mark Stevenson, Peter Dansky, Harald Berninger, Rik van Heijningen, Dimitri Pappaioannou, Sandor Snoeijers, Sharat Singh

Oct 02, 2007

Premium

Arthur Holden plans to leave his post as vice president of corporate and market development at Illumina in mid-October, the company said last week in a filing with the US Securities and Exchange Commission.

Holden is director of the Severe Adverse Events Consortium, a pharma-backed initiative that aims to find genetic causes for severe adverse events that hamper drug development.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Ex Vivo Imaging Quick Start Guide

Probe Design and In Vitro Validation Quick Start Guide

Oct

25

Featured Webinar

A Comprehensive Strategy for Evaluating NGS Liquid Biopsy and Tumor Tissue Assays

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate NGS oncology assays for genomic tumor profiling of plasma and tissue samples.

Main menu